Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$8.30 USD
-0.11 (-1.31%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $8.40 +0.10 (1.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TNGX 8.30 -0.11(-1.31%)
Will TNGX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TNGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNGX
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy?
TNGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?
Other News for TNGX
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
Barclays Issues a Buy Rating on Tango Therapeutics (TNGX)
Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data
First Week of September 20th Options Trading For Tango Therapeutics (TNGX)
Notable Two Hundred Day Moving Average Cross - TNGX